Lexicon Pharmaceuticals Stock Earnings Per Share

LXRX Stock

USD 0.77 0.04 4.94%

Lexicon Pharmaceuticals fundamentals help investors to digest information that contributes to Lexicon Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Lexicon Stock. The fundamental analysis module provides a way to measure Lexicon Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lexicon Pharmaceuticals stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Lexicon Pharmaceuticals Company Earnings Per Share Analysis

Lexicon Pharmaceuticals' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.

Earnings per Share

Earnings

Average Shares

More About Earnings Per Share | All Equity Analysis

Current Lexicon Pharmaceuticals Earnings Per Share

(0.74) X

Most of Lexicon Pharmaceuticals' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lexicon Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Lexicon Earnings Per Share Driver Correlations

Understanding the fundamental principles of building solid financial models for Lexicon Pharmaceuticals is extremely important. It helps to project a fair market value of Lexicon Stock properly, considering its historical fundamentals such as Earnings Per Share. Since Lexicon Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lexicon Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lexicon Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Long Term Debt	Property Plant Equipment	Good Will	Intangible Assets	Treasury Stock	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.39	0.51	-0.57	-0.11	0.47	0.18	0.88	0.78	0.98	0.33	0.53	0.35	0.32	0.43	0.75	0.1	0.1	-0.19	-0.16	0.62	-0.16	0.55	0.53	-0.4
Total Stockholder Equity	0.39		0.12	-0.55	0.31	0.18	-0.35	0.35	0.1	0.4	0.45	-0.12	-0.29	0.18	-0.09	0.34	0.43	0.54	-0.38	-0.25	0.34	0.31	0.3	0.25	-0.1
Current Deferred Revenue	0.51	0.12		-0.29	-0.43	0.59	0.09	0.64	0.57	0.61	-0.08	0.35	0.28	-0.25	0.37	0.09	-0.41	-0.13	0.31	0.45	0.72	-0.51	-0.05	-0.02	0.14
Net Debt	-0.57	-0.55	-0.29		-0.33	-0.17	0.48	-0.37	-0.15	-0.53	-0.34	-0.16	0.4	-0.42	-0.1	-0.58	-0.09	-0.55	0.63	0.41	-0.58	-0.22	-0.26	-0.14	0.42
Retained Earnings	-0.11	0.31	-0.43	-0.33		-0.26	-0.06	-0.16	-0.23	-0.13	0.34	-0.75	-0.43	0.52	-0.76	-0.02	0.51	0.6	-0.84	-0.85	0.03	0.58	0.56	0.48	-0.61
Accounts Payable	0.47	0.18	0.59	-0.17	-0.26		0.04	0.65	0.73	0.47	0.24	0.25	0.51	0.0	0.24	0.44	-0.07	-0.48	0.14	0.12	0.23	-0.1	0.24	0.21	-0.19
Net Receivables	0.18	-0.35	0.09	0.48	-0.06	0.04		0.3	0.36	0.23	0.13	0.04	0.56	-0.02	0.03	-0.24	-0.17	-0.2	0.2	0.01	-0.11	-0.11	0.47	0.58	-0.22
Short Term Investments	0.88	0.35	0.64	-0.37	-0.16	0.65	0.3		0.82	0.9	0.18	0.38	0.42	0.17	0.36	0.56	0.1	0.0	-0.09	0.02	0.6	-0.14	0.57	0.59	-0.25
Total Liab	0.78	0.1	0.57	-0.15	-0.23	0.73	0.36	0.82		0.79	0.17	0.35	0.79	0.11	0.31	0.55	0.01	-0.42	0.14	0.02	0.47	-0.44	0.5	0.49	-0.37
Total Current Assets	0.98	0.4	0.61	-0.53	-0.13	0.47	0.23	0.9	0.79		0.34	0.47	0.38	0.16	0.39	0.61	0.02	0.13	-0.1	-0.05	0.67	-0.23	0.52	0.51	-0.34
Short Term Debt	0.33	0.45	-0.08	-0.34	0.34	0.24	0.13	0.18	0.17	0.34		-0.04	0.01	0.18	-0.08	0.22	0.15	0.3	-0.35	-0.38	-0.14	0.5	0.47	0.44	-0.44
Common Stock	0.53	-0.12	0.35	-0.16	-0.75	0.25	0.04	0.38	0.35	0.47	-0.04		0.3	0.04	0.92	0.52	-0.35	-0.32	0.34	0.39	0.08	-0.28	-0.17	-0.14	0.16
Long Term Debt	0.35	-0.29	0.28	0.4	-0.43	0.51	0.56	0.42	0.79	0.38	0.01	0.3		-0.2	0.3	0.15	-0.2	-0.73	0.55	0.28	-0.02	-0.56	0.21	0.25	-0.14
Property Plant Equipment	0.32	0.18	-0.25	-0.42	0.52	0.0	-0.02	0.17	0.11	0.16	0.18	0.04	-0.2		-0.01	0.57	0.53	0.22	-0.74	-0.76	0.08	0.41	0.6	0.53	-0.56
Good Will	0.43	-0.09	0.37	-0.1	-0.76	0.24	0.03	0.36	0.31	0.39	-0.08	0.92	0.3	-0.01		0.38	-0.31	-0.32	0.36	0.54	0.04	-0.28	-0.18	-0.13	0.34
Intangible Assets	0.75	0.34	0.09	-0.58	-0.02	0.44	-0.24	0.56	0.55	0.61	0.22	0.52	0.15	0.57	0.38		0.28	-0.07	-0.38	-0.38	0.33	0.06	0.4	0.3	-0.47
Treasury Stock	0.1	0.43	-0.41	-0.09	0.51	-0.07	-0.17	0.1	0.01	0.02	0.15	-0.35	-0.2	0.53	-0.31	0.28		0.29	-0.52	-0.48	-0.02	0.4	0.5	0.48	-0.12
Net Tangible Assets	0.1	0.54	-0.13	-0.55	0.6	-0.48	-0.2	0.0	-0.42	0.13	0.3	-0.32	-0.73	0.22	-0.32	-0.07	0.29		-0.64	-0.41	0.27	0.51	0.25	0.23	-0.12
Long Term Debt Total	-0.19	-0.38	0.31	0.63	-0.84	0.14	0.2	-0.09	0.14	-0.1	-0.35	0.34	0.55	-0.74	0.36	-0.38	-0.52	-0.64		0.84	-0.16	-0.68	-0.62	-0.52	0.61
Capital Surpluse	-0.16	-0.25	0.45	0.41	-0.85	0.12	0.01	0.02	0.02	-0.05	-0.38	0.39	0.28	-0.76	0.54	-0.38	-0.48	-0.41	0.84		-0.03	-0.54	-0.65	-0.54	0.84
Deferred Long Term Liab	0.62	0.34	0.72	-0.58	0.03	0.23	-0.11	0.6	0.47	0.67	-0.14	0.08	-0.02	0.08	0.04	0.33	-0.02	0.27	-0.16	-0.03		-0.44	0.18	0.15	-0.14
Short Long Term Debt	-0.16	0.31	-0.51	-0.22	0.58	-0.1	-0.11	-0.14	-0.44	-0.23	0.5	-0.28	-0.56	0.41	-0.28	0.06	0.4	0.51	-0.68	-0.54	-0.44		0.38	0.34	-0.26
Net Invested Capital	0.55	0.3	-0.05	-0.26	0.56	0.24	0.47	0.57	0.5	0.52	0.47	-0.17	0.21	0.6	-0.18	0.4	0.5	0.25	-0.62	-0.65	0.18	0.38		0.98	-0.69
Net Working Capital	0.53	0.25	-0.02	-0.14	0.48	0.21	0.58	0.59	0.49	0.51	0.44	-0.14	0.25	0.53	-0.13	0.3	0.48	0.23	-0.52	-0.54	0.15	0.34	0.98		-0.58
Capital Stock	-0.4	-0.1	0.14	0.42	-0.61	-0.19	-0.22	-0.25	-0.37	-0.34	-0.44	0.16	-0.14	-0.56	0.34	-0.47	-0.12	-0.12	0.61	0.84	-0.14	-0.26	-0.69	-0.58

Click cells to compare fundamentals

Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.

Competition

Predict Lexicon Pharmaceuticals

Lexicon Pharmaceuticals Earnings Estimates

Lexicon Common Stock Shares Outstanding

Common Stock Shares Outstanding

232.19 Million

At this time, Lexicon Pharmaceuticals' Common Stock Shares Outstanding is fairly stable compared to the past year.

According to the company disclosure, Lexicon Pharmaceuticals has an Earnings Per Share of -0.74 times. This is 108.84% lower than that of the Biotechnology sector and 84.55% lower than that of the Health Care industry. The earnings per share for all United States stocks is 123.72% higher than that of the company.

Lexicon Earnings Per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lexicon Pharmaceuticals' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lexicon Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Lexicon Pharmaceuticals by comparing valuation metrics of similar companies.

Lexicon Pharmaceuticals is currently under evaluation in earnings per share category among its peers.

Lexicon Fundamentals

	Return On Equity	-1.36
	Return On Asset	-0.44
	Operating Margin	(36.40) %
	Current Valuation	134.7 M
	Shares Outstanding	361.49 M
	Shares Owned By Insiders	1.15 %
	Shares Owned By Institutions	82.00 %
	Number Of Shares Shorted	28.65 M
	Price To Earning	21.02 X
	Price To Book	1.64 X
	Price To Sales	53.35 X
	Revenue	1.2 M
	Gross Profit	(52.68 M)
	EBITDA	(163.46 M)
	Net Income	(177.12 M)
	Cash And Equivalents	61.97 M
	Cash Per Share	0.34 X
	Total Debt	106.06 M
	Debt To Equity	0.36 %
	Current Ratio	3.85 X
	Book Value Per Share	0.49 X
	Cash Flow From Operations	(161.9 M)
	Short Ratio	10.26 X
	Earnings Per Share	(0.74) X
	Price To Earnings To Growth	(0.14) X
	Target Price	5.08
	Number Of Employees	285
	Beta	1.24
	Market Capitalization	278.96 M
	Total Asset	229.43 M
	Retained Earnings	(1.77 B)
	Working Capital	145 M
	Current Asset	171.5 M
	Current Liabilities	31.77 M
	Net Asset	229.43 M

About Lexicon Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Lexicon Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lexicon Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lexicon Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Lexicon Stock Analysis

When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC